Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

Neurology

Volumn 75, Issue 5, 2010, Pages 403-410

  Mehling, M ^a   Lindberg, R ^a   Raulf, F ^b   Kuhle, J ^a   Hess, C ^a   Kappos, L ^a   Brinkmann, V ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; INTERLEUKIN 17;

ADULT; ARTICLE; BLOOD CELL; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TH17 CELL; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD3; ANTIGENS, CD4; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; INTERLEUKIN-17; MALE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; PROSPECTIVE STUDIES; RECEPTORS, CCR4; RECEPTORS, CCR6; SPHINGOSINE; T-LYMPHOCYTES;

EID: 77955358808     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ebdd64     Document Type: Article

References (30)

1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9:393-407.
2. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-1133.
3. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-104.
4. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemo-kine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-523.
5. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009;132:3329-3341.
6. Montes M, Zhang X, Berthelot L, et al. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol 2009;130:133-144.
7. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-155.
8. Kebir H, Kreymborg K, Ifergan I, et al. Human T(H)17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13: 1173-1175.
9. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-332.
10. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401: 708-712.
11. Kappos L, Antel J, Comi G, et al. Oral Fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
12. Cohen JA, Barkhof F, Comi G, et al. Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
13. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral Fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
14. O'Connor P, Comi G, Montalban X, et al. Oral Fingoli-mod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79.
15. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
16. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8:639-646.
17. Brucklacher-Waldert V, Steinbach K, Lioznov M, Kolster M, Holscher C, Tolosa E. Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. J Immunol 2009;183:5494-5501.
18. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007;8: 913-919.
19. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
20. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509.
21. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009;183:5418-5427.
22. Liu M, Hu X, Wang Y, et al. Effect of high-dose methyl-prednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse. Acta Neurol Scand 2009;120: 235-241.
23. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-852.
24. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22: 745-763.
25. Plumb J, Armstrong MA, Duddy M, Mirakhur M, Mc-Quaid S. CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult Scler 2003;9:142-147.
26. Serafini B, Rosicarelli B, Magliozzi R, et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuro-pathol Exp Neurol 2006;65:124-141.
27. Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004;55:627-638.
28. Hofstetter H, Gold R, Hartung HP. Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis. Int MS J 2009;16:12-18.
29. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009;183:7169-7177.
30. Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009;119: 61-69.